Iratumumab
This article needs additional citations for verification. (August 2012) |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD30 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6358H9830N1682O1992S38 |
Molar mass | 142922.64 g·mol−1 |
(what is this?) (verify) |
Iratumumab is a
Hodgkin's disease.[1]
This drug was developed by
Bristol-Myers Squibb
.
The FDA granted
orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given.[2]
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Iratumumab, American Medical Association.
- ^ "Iratumumab". AdisInsight. Retrieved 30 January 2017.